Bioinformatics Meets Systems Biology for Early Stage Drug Discovery
The notion of one drug binding to one receptor to treat one condition I will argue may be more of an exception than the rule. Rather polypharmacology dictates action of a drug against multiple targets; but what are those targets? I will describe bioinformatics techniques for ascertaining those targets and subsequently using techniques from systems biology to determine the expected phenotype. Examples will illustrate explanations for possible drug side effects and repositioning of existing drugs to treat a different condition. More details can be found at http://www.sdsc.edu/pb (drug discovery)
Department of Pharmacology & Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego
Philip E. Bourne PhD is a Professor in the Department of Pharmacology and Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego, Associate Director of the RCSB Protein Data Bank and an Adjunct Professor at the Burnham Institute. He is a Past President of the International Society for Computational Biology. He is an elected fellow of the American Association for the Advancement of Science (AAAS) and the American Medical Informatics Association (AMIA). He is the co-founder and Editor-in-Chief of the open access journal PLoS Computational Biology and a long standing member of the National Science Foundation, National Institutes of Health and Genome Canada panels responsible for reviewing proposals relating to computational biology.
Awards include: the Jim Gray eScience Award (2010), the Benjamin Franklin Award (2009), the Flinders University Convocation Medal for Outstanding Achievement (2004) and the Sun Microsystems Convergence Award (2002).
Bourne's professional interests focus on relevant biological and educational outcomes derived from computation and scholarly communication. This implies algorithms, text mining, machine learning, metalanguages, biological databases, and visualization applied to problems in drug discovery, evolution, cell signaling, apoptosis, systems biology and scientific dissemination. He has published over 200 papers and 5 books, one of which sold over 150,000 copies. He has co-founded 4 companies: ViSoft Inc., Protein Vision Inc., a company distributing independent films for free and most recently SciVee.
Bourne is committed to furthering the free dissemination of science through new models of publishing and better integration and subsequent dissemination of data and results which as far as possible should be freely available to all.
Personal interests are squash, hiking, skiing, flying and motor bikes.